Erratum to: Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction – a randomised placebo-controlled trial (KARE): study protocol
© The Author(s). 2017
Received: 6 April 2017
Accepted: 6 April 2017
Published: 11 May 2017
In the original publication  the last sentence under the paragraph “Adverse event management” not correct. The correct version can be found here:
“SAEs that occur between trial entry and up to 28 days after completion of the study drug will be reported”.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- McAuley DF. Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction – a randomised placebo-controlled trial (KARE): study protocol. Trials. 2013;14:10.1186/1745-6215-14-51.Google Scholar